



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: pcGNM2/TSG-F (TSG101)

Catalog Number: 11483

Lot Number: 080143

Release Category: C

Provided: 5 µg of dried purified DNA stabilized in DNASTable *PLUS*

Cloning Site: XbaI and BamHI (Insert size, 1196bp).

Cloning Vector: pcGNM2 (The size of the cloning vector, including insert, is 6230bp).

Description: Full-length TSG101 expression vector. Constructed by transferring the TSG101 coding region from plasmid pGST2/TSG5 (provided by Z. Sun). For more details, see *Goila-Gaur et.al.* (2003).

Special Characteristics: Over expression of pcGNM2/TSG-F inhibits HIV-1 budding.
[Donor Sequence](#)
[Donor Plasmid Map](#)
[Sequence file lot 080143](#)

This reagent is currently being provided as dried purified DNA stabilized in DNASTable *PLUS*. Please see the notice for additional information and the protocol for reconstitution of dried DNA reagents. [Dried DNA Notice](#)

Recommended Storage: Keep the reagent at room temperature in a dry storage cabinet or in a moisture barrier bag.

Contributor: Dr. Eric Freed

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 over expression. *J Virol.* 2003, **77** (11); 6507-19.

Demirov DG, Ono A, Orenstein JM, Freed EO. Over expression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. *Proc. Natl. Acad. Sci. USA*, 2002, **99** (2); 955-60.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: pcGNM2/TSG-F (Cat#11483) from Dr. Eric Freed." Also include the references cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NIH Office of Technology Transfer, Email: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.

Last Updated:

October 22, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.